PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-26.68%
Both companies show declining cash positions (-26.68% vs AXSM's -18.81%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-26.68%
Cash + STI yoy 1.25-1.5x AXSM's -18.81%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-45.50%
Higher Other Current Assets Growth compared to AXSM's zero value, indicating worse performance.
-27.05%
1.25-1.5x AXSM's -18.93%. Bruce Berkowitz checks if strong current asset growth is used effectively.
-7.44%
Below half AXSM's -15.20%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both AXSM and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
12.75%
Higher Other Non-Current Assets Growth compared to AXSM's zero value, indicating worse performance.
-5.69%
≥ 1.5x AXSM's -2.95%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-25.21%
1.25-1.5x AXSM's -18.87%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
9.15%
Less than half of AXSM's 53.94%. David Dodd sees a more disciplined AP approach or lower volume.
-74.86%
Similar yoy changes to AXSM's -69.91%. Walter Schloss finds a parallel approach to short-term funding.
No Data
No Data available this quarter, please select a different quarter.
-9.15%
Below half of AXSM's 79.44%. Michael Burry suspects a big gap in pre-sales traction.
No Data
No Data available this quarter, please select a different quarter.
7.01%
Less than half of AXSM's 41.61%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.56%
Less than half of AXSM's 9.66%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
4.31%
Less than half of AXSM's 23.36%. David Dodd sees far fewer liability expansions relative to competitor.
1.65%
Above 1.5x AXSM's 0.50%. Michael Burry suspects heavy new equity expansion or dilution.
-3.34%
Below half AXSM's -14.50%. Michael Burry suspects major net losses or high dividends vs. competitor.
-6.51%
Less than half of AXSM's -200.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-36.72%
Below half AXSM's 105.17%. Michael Burry sees potential underperformance in building shareholder capital.
-25.21%
Below half AXSM's 143.80%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Both AXSM and the company show zero Total Investments Growth.
-11.75%
Less than half of AXSM's 0.90%. David Dodd sees less overall debt expansion vs. competitor.
27.85%
Similar yoy changes to AXSM's 30.11%. Walter Schloss sees parallel net leverage strategies.